Tumor Necrosis Factor

Tumor Necrosis Factor - most related articles:

- TNF blockers will have boxed warning cancer risk - 6.5
- Osteoporosis drugs increase bone necrosis risk - 5.4
- Cimzia in prefilled syringe for Crohn's disease patients - 4.8
- Obesity enhances liver cancer risk - 4.5
- Breast cancer markers discovered in breast cancer survivors - 3.9
- UCB's Cimzia approved for rheumatoid arthritis adults - 3.8
- Herpes zoster or shingles risk more with rheumatoid arthritis medicines - 3.5
- Cell phone usage not causing brain tumor - 3.4
- HER growth proteins do not predict outcome of herceptin treatment breast cancer patients - 3.2
- Altered genes play role in development of brain tumors - 3.2

Tumor Necrosis Factor articles

4 times cancer rate in children with juvenile arthritis
New research reports that incident malignancy among children with juvenile idiopathic arthritis (JIA) is four times higher than in those without the disease. Findings suggest JIA treatment, such as tumor necrosis factor (TNF) inhibitors, does not necessarily explain the development of cancer in this pediatric population.

Actemra, tocilizumab approved for Rheumatoid Arthritis
Genentech, Inc. , a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

TNF blockers will have boxed warning cancer risk
The U.S. Food and Drug Administration is requiring stronger warnings in the prescribing information for a class of drugs known as TNF blockers or TNF inhibitors.

Cimzia in prefilled syringe for Crohn's disease patients
Cimzia (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) for reducing signs and symptoms of Crohn's disease is now available for self-administration in a prefilled syringe.

UCB's Cimzia approved for rheumatoid arthritis adults
UCB announced that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

Herpes zoster or shingles risk more with rheumatoid arthritis medicines
Use of certain medications known as monoclonal anti tumor necrosis factor a (TNF-a) antibodies for the treatment of rheumatoid arthritis appears to be associated with an increased risk for herpes zoster (shingles), the painful infection characterized by blisters, according to a study in the February 18 issue of JAMA.

6 Tumor Necrosis Factor articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
4.35